Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Zhejiang Taimei Medical Technology Co Ltd Class H ( (HK:2576) ) just unveiled an update.
Zhejiang Taimei Medical Technology reported audited results for 2025 showing it remains focused on AI-powered clinical development solutions, having supported over 10,000 clinical trials since inception. Its platform strategy centers on integrating software infrastructure and proprietary clinical AI models trained on exclusive data to accelerate and de-risk the clinical development process for sponsors.
For 2025, the company recorded revenue of RMB512.5 million, down 7.0% year on year, as it deliberately optimized its revenue mix toward higher-margin business. Despite the revenue decline, gross profit margin improved to 42.4%, new bookings rose 36.3% to RMB697.5 million, and the annual loss narrowed sharply to RMB50.7 million, highlighting tighter cost discipline and a clearer path toward profitability.
Non-IFRS metrics also improved, with adjusted net loss reduced to RMB49.5 million and adjusted EBITDA loss shrinking compared with 2024. Management attributed these trends to focused product investment, stronger demand for larger multi-year enterprise contracts, and better monetization of its platform and services.
The most recent analyst rating on (HK:2576) stock is a Hold with a HK$5.00 price target. To see the full list of analyst forecasts on Zhejiang Taimei Medical Technology Co Ltd Class H stock, see the HK:2576 Stock Forecast page.
More about Zhejiang Taimei Medical Technology Co Ltd Class H
Zhejiang Taimei Medical Technology Co., Ltd. is a leading AI-driven platform provider for clinical development, offering full-stack digital infrastructure for clinical trials. The company combines software, modular AI tools, and clinical development solutions to help drug sponsors streamline workflows, improve trial success rates, and comply with global regulatory standards.
Average Trading Volume: 50,327
Technical Sentiment Signal: Strong Buy
Current Market Cap: HK$2.72B
Find detailed analytics on 2576 stock on TipRanks’ Stock Analysis page.